We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
No comments yet, be the first to start the discussion!
ipi and nivo or try a nivo and lag3 phase 3 trial
No information on BRAF status. Ipi+Nivo. If BRAFpositive BRAF/MEKi is also possible
use of combination BRAFi + MEKi possible
Rosane JohnsaoJohnsson n
ipi and nivo
if possible inhibitor BRAF and MEK
Alexander van Akkooi
I think everybody has suggested proven good therapeutic options in this case. Clinical trial is always an option, if you have one open at your site for such a patient. Having said this, we don't actually know what is the best 2nd line treatment after failing adjuvant anti-PD-1 or first line anti-PD-1. There are no prospective randomized trials looking at BRAF/MEK, IPI or IPI/NIVO in this situation. From some retrospective series, IPI/NIVO seems superior to IPI alone. BRAF/MEK obviously also an option, but only for those with a BRAF mutation.
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.